Stéphane Bancel

This is a momentous milestone in Moderna's history as it is our first product to achieve licensure in the U.S., the full licensure of Spikevax in the U.S. now joins that in Canada, Japan, the European Union, the UK, Israel, and other countries, where the adolescent indication is also approved. We are grateful to the U.S. FDA for their thorough review of our application. We are humbled by the role that Spikevax is playing to help end this pandemic.

Stéphane Bancel

For several days, we have been moving as fast as possible to execute our strategy to address this variant.

Stéphane Bancel

It is promising to see clinical and real-world evidence adding to the growing body of data on the effectiveness of the Moderna COVID-19 vaccine.

Stéphane Bancel

This BLA submission for our COVID-19 vaccine, which we began in June, is an important milestone in our battle against COVID-19 and for Moderna CEO Stéphane Bancel, as this is the first BLA submission in our company's history.

Stéphane Bancel

Today, we know that we can get an mRNA vaccine authorized by the regulator. And in business, (the difference) between believing and knowing is a huge difference in your willingness to take the risk.

Stéphane Bancel